Orthopedic outcome studies and cost issues.
Standard therapy for years was on-demand therapy. Readers will learn of results of clinical experience in many different countries with a prophylactic approach to therapy as well as ongoing experimental designs to define optimal therapy. The costs of current prophylaxis regimens will be discussed.
Aledort
Louis M
LM
Mount Sinai School of Medicine, New York, New York 10029-6574, USA. louis.aledort@mssm.edu
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D004305:Dose-Response Relationship, Drug; D006467:Hemophilia A / Q000628:therapy*; D002836:Hemophilia B / Q000628:therapy*; D006801:Humans; D009985:Orthopedics / Q000379:methods*; D017063:Outcome Assessment, Health Care; D016896:Treatment Outcome